Maizi Ali Mohamed

Maizi Ali Mohamed of Leerink Partners inquired about the outlook for VASCEPA's net pricing in the U.S. amid increasing rebates and asked if additional clinical trials could accelerate reimbursement for VAZKEPA in the EU and China.

Answer

President and CEO Aaron Berg acknowledged that U.S. rebate pressures will likely continue due to generic competition but stated the company can still compete profitably. Regarding European reimbursement, Dr. Steven Ketchum, EVP of R&D, and Mr. Berg explained that while they continue to generate supportive data, they believe their current clinical package is strong and that reimbursement timelines are more reflective of broad market challenges in Europe rather than a data deficiency. They noted a focus on high-risk patient subgroups is helping accelerate uptake.